Nervgen Pharma (NGEN) Total Non-Current Liabilities (2024 - 2026)

Nervgen Pharma (NGEN) has reported Total Non-Current Liabilities for 3 consecutive years, with $15.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $15.6 million in Q2 2026; TTM through Jun 2026 was $15.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.8 million, up 95423.05% from the prior year.
• Total Non-Current Liabilities was $15.6 million for Q2 2026 at Nervgen Pharma, up from $8.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $15.6 million in Q2 2026 and troughed at $5990.9 in Q4 2024.
• A 3-year average of $7.4 million and a median of $7.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The widest YoY moves for Total Non-Current Liabilities: up 97364.64% in 2025, down 97364.64% in 2025.
• Over 3 years, Total Non-Current Liabilities stood at $5990.9 in 2024, then jumped by 97364.64% to $5.8 million in 2025, then soared by 166.99% to $15.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $15.6 million (Q2 2026), $8.3 million (Q1 2026), and $5.8 million (Q4 2025), per Business Quant data.